Abstract
Acutely ill medical patients with reduced mobility are at increased risk of venous thromboembolism, which can occur during hospitalization or after discharge. A number of clinical trials and meta-analyses have shown that pharmacologic prophylaxis with anticoagulant drugs in these patients significantly reduces the risk of fatal pulmonary embolism as compared to placebo or no treatment, without significant increase in the risk of major bleeding. Thus, the use of anticoagulant prophylaxis is recommended for all high risk medical patients during hospitalization. To identify these high risk patients, clinicians may use the inclusion criteria applied in the trials, with a selection that is mostly qualitative, or risk assessment models, with a selection that is both qualitative and quantitative. With both approaches, about 40 % of medical patients would be at increased risk of venous thrombosis. Because in the real world medical patients tend to be much older and with more comorbidities than in clinical trials, patient selection needs to also take into account risk factors for bleeding. Among others, estimation of creatinine clearance appears to be particularly important to prevent excessive exposure to anticoagulant drugs. Finally, although the risk of venous thrombosis may persist in some patients after hospital discharge, clinical trials assessing extended prophylaxis in this setting have failed to show a convincing clinical benefit with this approach.
Similar content being viewed by others
References
Goldhaber SZ, Tapson VF (2004) A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 93:259–262
Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ (2007) Venous thromboembolism in the outpatient setting. Arch Intern Med 167:1471–1475
Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsard D, Decousus H (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or low molecular weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83:14–19
Samama MM, Cohen AT, Darmon JY et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341:793–800
Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879
Cohen AT, Davidson BI, Gallus AS et al (2006) Efficacy and safety of fondaparinux for the prevention of VTE in older acute medical patients. BMJ 332:325–329
Dentali F, Douketis JD, Gianni M, Lim W, Crowther M (2007) Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Inter Med 146:278–288
Kahn S, Lim W, Dunn AS et al (2012) Prevention of VTE in non surgical patients. Chest 141(2):Suppl:e195S–e226S
Cohen AT, Tapson VF, Bergmann JF et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394
Tapson VF, Decousus H, Pini M et al (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 132:936–945
Gussoni G, Campanini M, Silingardi M, Scannapieco G, Mazzone A, Magni G, Valerio A, Iori I, Ageno W (2009) In hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Findings from a multicenter, prospective study. Thromb Haemost 101:893–901
Ageno W, Squizzato A, Ambrosini F, Dentali F, Marchesi C, Mera V, Steidl L, Venco A (2002) Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 87:746–750
Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence-based-clinical practice guidelines (8th edition). Chest 133:381–453
Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8:2450–2457
Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA (2008) Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. J Thromb Haemost 6:405–414
Decousus H, Tapson VF, Bergmann JF et al (2011) Factors at admission associated with bleeding risk in medical patients. Findings from the IMPROVE Investigators. Chest 139:69–79
Hull RD, Schellong SM, Tapson VF et al (2010) Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 153:8–18
Cohen AT, Spiro TE, Büller HR et al (2011) Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. American College of Cardiology Congress 60th Annual Scientific Session, New Orleans, USA
Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2177
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ageno, W. Do medical patients need to receive pharmacologic prophylaxis for the prevention of venous thromboembolism?. Intern Emerg Med 7 (Suppl 3), 189–192 (2012). https://doi.org/10.1007/s11739-012-0800-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-012-0800-2